China suspends imports of Daewoong Bio's antibiotic over law violation

Daewoong (Seongnam-si)

18/07/2024 15:40

BEIJING, July 18 (Reuters) - China has suspended the
import, sale and use of Daewoong Bio's cefodizime sodium for
injection, after the South Korean company rejected an inspection
request at its production site, the Chinese medical regulator
said on Thursday. 
    Daewoong Bio's move violated China's Drug Administration Law
and regulations on overseas inspection of drugs and medical
devices, the National Medical Products Administration said in a
statement.
    Cefodizime sodium is an antibiotic that treats a variety of
bacterial infections and is sometimes prescribed for people who
are allergic to penicillin, another form of antibiotic.

 (Reporting by Ethan Wang and Ryan Woo; Editing by Kirsten
Donovan)
 ((Ethan.Wang@thomsonreuters.com;))